Eyepoint Pharmaceuticals Inc (EYPT) Director Purchases $69,600.00 in Stock

Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) Director John B. Landis acquired 40,000 shares of the firm’s stock in a transaction on Monday, May 13th. The stock was purchased at an average price of $1.74 per share, for a total transaction of $69,600.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

NASDAQ:EYPT traded up $0.04 during mid-day trading on Wednesday, hitting $1.83. 301,572 shares of the company’s stock were exchanged, compared to its average volume of 398,239. Eyepoint Pharmaceuticals Inc has a one year low of $1.24 and a one year high of $3.94. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.57 and a quick ratio of 2.57. The firm has a market capitalization of $187.82 million, a P/E ratio of -3.16 and a beta of 1.89.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.03). Eyepoint Pharmaceuticals had a negative return on equity of 174.26% and a negative net margin of 1,739.81%. The business had revenue of $2.01 million for the quarter, compared to the consensus estimate of $3.70 million. On average, equities research analysts expect that Eyepoint Pharmaceuticals Inc will post -0.4 earnings per share for the current fiscal year.

A number of brokerages have recently weighed in on EYPT. ValuEngine lowered shares of Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, March 21st. Zacks Investment Research lowered shares of Eyepoint Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, April 22nd. Finally, HC Wainwright set a $5.00 price objective on shares of Eyepoint Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, April 2nd.

A number of large investors have recently bought and sold shares of the stock. Vanguard Group Inc boosted its stake in Eyepoint Pharmaceuticals by 2.7% during the third quarter. Vanguard Group Inc now owns 1,798,708 shares of the company’s stock worth $6,422,000 after acquiring an additional 47,361 shares in the last quarter. Vanguard Group Inc. boosted its stake in Eyepoint Pharmaceuticals by 2.7% during the third quarter. Vanguard Group Inc. now owns 1,798,708 shares of the company’s stock worth $6,422,000 after acquiring an additional 47,361 shares in the last quarter. BlackRock Inc. boosted its stake in Eyepoint Pharmaceuticals by 712.5% during the fourth quarter. BlackRock Inc. now owns 1,232,335 shares of the company’s stock worth $2,329,000 after acquiring an additional 1,080,662 shares in the last quarter. Essex Investment Management Co. LLC boosted its stake in Eyepoint Pharmaceuticals by 322.4% during the fourth quarter. Essex Investment Management Co. LLC now owns 568,141 shares of the company’s stock worth $1,074,000 after acquiring an additional 433,632 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in Eyepoint Pharmaceuticals by 33.4% in the fourth quarter. Geode Capital Management LLC now owns 417,597 shares of the company’s stock worth $789,000 after buying an additional 104,582 shares during the last quarter. 51.93% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Eyepoint Pharmaceuticals Inc (EYPT) Director Purchases $69,600.00 in Stock” was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.chaffeybreeze.com/2019/05/15/eyepoint-pharmaceuticals-inc-eypt-director-purchases-69600-00-in-stock.html.

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. It provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis (NIPU) that is in the Phase III clinical trials; and Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis.

Read More: What is the Fibonacci sequence?

Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.